Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic,microalbuminuric subjects

Abstract

Introduction. Elevated plasma matrix metalloproteinase-9 (MMP-9) levels have been suggested to precede the development of microalbuminuria. As angiotensin-converting enzyme (ACE) inhibitors effectively reduce urinary albumin excretion (UAE), in the present study we have investigated the potential association of plasma MMP-9 levels with UAE and treatment effects of ACE-inhibition. Material and methods. In a placebo-controlled

randomised trial we determined plasma MMP-9 levels at baseline and after three months of randomisation to either placebo (n=202) or fosinopril (20 mg/day, n=204) treatment.

Results. Baseline plasma MMP-9 levels were not related to baseline UAE (r=-0.008, p=0.871).Three months of fosinopril treatment effectively reduced UAE compared to placebo treatment (-10.4±2.4 vs. 1.8±1.3 mg/24 hours, p<0.001, respectively). However, fosinopril treatment failed to significantly change plasma MMP-9 levels compared to placebo (-0.47±7.68 vs. 0.06±9.20, p=0.646, respectively) . In addition, the change in UAE was not related with change in MMP-9 levels.

Conclusion. The effective reduction of UAE with fosinopril was not related to plasma MMP-9 levels.

Keywords

angiotensin-converting enzyme ACE-inhibitors fosinopril matrix metalloproteinase-9 urinary albumin excretion

Get full access to this article

View all access options for this article.

References

Deckert T. , Feldt-Rasmussen B. , Borch-Johnsen K. , Jensen T. , Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis . Diabetologia 1989;32:219-26.

Yuyun MF , Khaw KT , Luben R. et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004;159:284-93.

Hillege HL , Fidler V. , Diercks GF et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-82.

Gerstein HC , Mann JF , Yi Q. et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.

Bigazzi R. , Bianchi S. , Baldari D. , Campese VM Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998;16:1325-33.

Jensen JS , Feldt-Rasmussen B. , Borch-Johnsen K. , Clausen P. , Appleyard M. , Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997;11:727-32.

Allen KV , Walker JD Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care 2003;26:2389-91.

Romundstad S. , Holmen J. , Kvenild K. , Hallan H. , Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis 2003;42:466-73.

Borch-Johnsen K. , Feldt-Rasmussen B. , Strandgaard S. , Schroll M. , Jensen JS Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992-7.

10.

Kannel WB , Stampfer MJ , Castelli WP , Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984;108:1347-52.

11.

Asselbergs FW , Diercks GF , Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria . Circulation 2004;110:2809-16.

12.

Parving HH , Hommel E. , Smidt UM Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988;297:1086-91.

13.

Ravid M. , Savin H. , Jutrin I. , Bental T. , Katz B. , Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients . Ann Intern Med 1993;118:577-81. 14. Effects of ramipril on cardiovascular and microvascular

14.

outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9. 15. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing

15.

microalbuminuria in type 2 diabetes. N Engl J O Med 2004;351:1941-51.

16.

Viberti G. , Mogensen CE , Groop LC , Pauls JF Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994;271:275-9. converting enzyme inhibitors and progression of nondiabetic

17.

Jafar TH , Schmid CH , Landa M. et al. Angiotensinconverting progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87.

18.

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-63.

19.

van de Wal RM , Gansevoort RT , van der Harst P. et al. Predictors of Angiotensin-Converting Enzyme Inhibitor-Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients. Hypertension 2006;48:870-6.

20.

van de Wal RM , Plokker HW , Lok DJ et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition . Int J Cardiol 2006 ;106:367-72.

21.

Tsilibary EC Microvascular basement membranes in diabetes mellitus. J Pathol 2003;200:537-46.

22.

Ebihara I. , Nakamura T. , Shimada N. , Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1998;32:544-50.

23.

Diercks GF , Janssen WM , van Boven AJ et al. Rationale, design M ,and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol 2000;86:635-8.

24.

Sundstrom J. , Evans JC , Benjamin EJ et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study . Circulation 2004;109:2850-6.

25.

Boffa JJ , Lu Y. , Placier S. , Stefanski A. , Dussaule JC , Chatziantoniou C. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J Am Soc Nephrol 2003;14:1132-44.

26.

Tashiro K. , Koyanagi I. , Ohara I. et al. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 2004;18:206-10.